Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference.

Novartis CEO Vas Narasimhan said: "I would like to thank Liz for her leadership and her contributions to our business and our patients this past year. She made a significant positive impact on the ...

I was at Novartis headquarters in Basel yesterday ... While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal ...

The news sparked a near-5% rise in Novartis’ share price. Chief executive Vas Narasimhan said performance was good “across all key growth brands and geographies” and “gives us continued ...

Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront. The Italian ...

Novartis chief executive Vas Narasimhan said the partnership “will help us deliver on our purpose to reimagine medicine to improve and extend lives,” while his counterpart at Microsoft ...

Novartis said this morning that Bradner (pictured ... could see a headcount reduction of 8,000 as chief executive Vas Narasimhan chases down $1.5 billion in cost reductions.

Novartis is paying $678 million to settle ... embedded at the heart of our company,” asserted chief executive Vas Narasimhan. Eisai has retreated from the optimistic view of sales growth for ...

Novartis is continuing a streak of pipeline ... according to comments made by chief executive Vas Narasimhan at the group’s R&D update last November. Eisai has retreated from the optimistic ...